Dermatology · Birmingham area, AL
Dermatology and skin studies in Birmingham area, AL
24 recruiting studies have a site in the Birmingham area. This page includes nearby cities such as Hoover, Homewood, Vestavia Hills, Bessemer.
24 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Birmingham, AL + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Birmingham, AL + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Birmingham, AL + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Birmingham, AL + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 22 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- Birmingham, AL + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Birmingham, AL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc.
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Birmingham, AL + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Birmingham, AL + 12 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
- Location
- Birmingham, AL + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
UCB Biopharma SRL
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
InventisBio Co., Ltd
- Location
- Birmingham, AL + 2 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 6 mo–11
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Birmingham, AL + 53 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingHealthy volunteers
Regulation of Inflammatory Genes in Psoriasis
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 19–99
- RecruitingHealthy volunteers
Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair
The Center for Clinical and Cosmetic Research
- Location
- Birmingham, AL + 1 other US site
- Eligibility basics
- Ages 28–65 · Women only
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.